New insights into cell-based therapy for heart failure from the CHART-1 study.

about

New insights into cell-based therapy for heart failure from the CHART-1 study.

Item

http://www.wikidata.org/entity/Q49833988

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

New insights into cell-based therapy for heart failure from the CHART-1 study.

@en

New insights into cell-based therapy for heart failure from the CHART-1 study.

@nl

type

Item

label

New insights into cell-based therapy for heart failure from the CHART-1 study.

@en

New insights into cell-based therapy for heart failure from the CHART-1 study.

@nl

prefLabel

New insights into cell-based therapy for heart failure from the CHART-1 study.

@en

New insights into cell-based therapy for heart failure from the CHART-1 study.

@nl

P1476

New insights into cell-based therapy for heart failure from the CHART-1 study.

@en

P2093

Angela C Rieger

http://www.w3.org/2001/XMLSchema#string

Bryon A Tompkins

http://www.w3.org/2001/XMLSchema#string

Joshua M Hare

http://www.w3.org/2001/XMLSchema#string

Monisha N Banerjee

http://www.w3.org/2001/XMLSchema#string

Victoria Florea

http://www.w3.org/2001/XMLSchema#string

P2860

Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease

Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells

Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.

Intramyocardial, autologous CD34+ cell therapy for refractory angina.

Cell-based therapy for prevention and reversal of myocardial remodeling

Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial

Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.

Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.

Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis.

Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy.

P304

1530-1533

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1002/EJHF.955

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28948676

http://www.w3.org/2001/XMLSchema#string

P921

heart failure

P932

5796677

http://www.w3.org/2001/XMLSchema#string